Robert Bradway - Amgen

Robert Bradway
CEO, Amgen

Total Compensation: $13.57 million

Professional Profile: Before Robert Bradway, 50, joined Amgen ($AMGN), he was an investment banker. Bradway spent more than 20 years at Morgan Stanley, 16 of them in London. He started his Amgen career in 2006 as a VP for operations strategy and moved up to the CFO job soon after. In 2010, he became president and COO, and then took over as CEO in May 2012. He has held the chairman's job as well since January 2013. An Amherst College graduate, he earned an MBA at Harvard Business School.

Compensation Breakdown: $1.26 million in salary, $8.57 million in stock, and $3.31 million in incentive pay, plus $420,059 in perks and other compensation.

Company Performance: Last year, Amgen started looking like a member of the Big Pharma clique. It bought a branded generics company in Turkey, MN Pharma, for $700 million, in a bid to diversify both geographically--into emerging markets--and product-wise. It caught some flak for its high-dollar lobbying in Washington. It gave up on one of its development programs, a treatment for pancreatic cancer. And toward the end of the year, it pleaded guilty to a criminal drug-misbranding charge and agreed to pay $762 million in fines and civil penalties to wrap up a federal investigation into its Aranesp marketing. Financially, however, the company remained firmly in Big Biotech. It beat analyst expectations with an 11% increase in 2012 sales, thanks to growth from its longtime autoimmune blockbuster Enbrel and its new bone drugs Prolia and Xgeva.

For more:
Special Reports: Robert A. Bradway - The 25 most influential people in biopharma today | Enbrel - The 15 best-selling drugs of 2012 | Amgen - The Biggest R&D Spenders in Biotech
Amgen tops forecasts for Q4, thanks to new drugs and higher prices
Amgen's two chiefs together net $22.7M in 2012 pay
Amgen pleads guilty in $762M Aranesp settlement
Did anemia drug giants game the system to rake in billions?

Robert Bradway - Amgen
Read more on

Suggested Articles

Oklahoma politicians contend J&J should be on the line for future abatement costs even after a $572 million verdict, but J&J sees things differently.

Abbott helmsman Miles White, who oversaw the spinoffs of AbbVie and Hospira, will step down as CEO after 21 years at the top job.

Mylan is the most recent drugmaker facing the FDA's ire over a tainted API that led to a global recall of "sartan"-based drugs last year.